Bhaskar ST, Dholaria BR, Sengsayadeth SM, Savani BN, Oluwole OO. Role of bridging therapy during chimeric antigen receptor T cell therapy. EJHaem. 2022;3:39–45.

Article  PubMed  Google Scholar 

Afrough A, Hashmi H, Hansen D, Sidana S, Ahn C, Peres L, et al. Real-World Impact of Bridging Therapy on Outcomes of Ide-cel for Myeloma in the U.S. Myeloma Immunotherapy Consortium. Blood Cancer J. 2023. https://doi.org/10.21203/rs.3.rs-3477431/v1

Mikhael J, Fowler J, Shah N. Chimeric antigen receptor T-cell therapies: barriers and solutions to access. JCO Oncol Pr. 2022;18:800–7.

Article  Google Scholar 

Ababneh HS, Yee AJ, Raje NS, Martin S, Frigault MJ, Ng AK, et al. Radiation therapy as a bridging and salvage strategy in patients with relapsed or refractory multiple myeloma undergoing BCMA-targeted CAR T-cell therapy. Radiother Oncol. 2023;189:109933. https://doi.org/10.1016/j.radonc.2023.109933.

Article  CAS  PubMed  Google Scholar 

Sim AJ, Jain MD, Figura NB, Chavez JC, Shah BD, Khimani F, et al. Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma. Int J Radiat Oncol Biol Phys. 2019;105:1012–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hubbeling H, Silverman EA, Michaud L, Tomas AA, Shouval R, Flynn J, et al. Bridging radiation rapidly and effectively cytoreduces high-risk relapsed/refractory aggressive B cell lymphomas prior to chimeric antigen receptor T cell therapy. Transpl Cell Ther. 2023;29:259.e1–259.e10.

Article  CAS  Google Scholar 

Zafar A, Huang C-Y, Lo M, Arora S, Chung A, Wong SW, et al. Intensity of cyclophosphamide-based bridging therapy before chimeric antigen receptor T cell therapy in myeloma. Transpl Cell Ther. 2023;29:504.e1–504.e7.

Article  CAS  Google Scholar 

Pinnix CC, Gunther JR, Dabaja BS, Strati P, Fang P, Hawkins MC, et al. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Adv. 2020;4:2871–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Akhtar OS, Modi K, Kim J, Skelson L, Smith E, Al-Jumayli MA, et al. Simple score of albumin and CRP predicts high-grade toxicity in patients with multiple myeloma receiving CAR-T therapy. Transpl Cell Ther. 2023;S2666-6367:01745–1.

Google Scholar 

Liu Y, Jie X, Nian L, Wang Y, Wang C, Ma J, et al. A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells. Front Immunol. 2023;14:1169071. https://doi.org/10.3389/fimmu.2023.1169071.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pan D, Mouhieddine TH, Fu W, Moshier E, Parekh S, Jagannath S, et al. Outcomes after CAR T cells in multiple myeloma patients with extramedullary and paramedullary disease. Blood. 2023;142:1006.

Article  Google Scholar